Cefquinome

Cefquinome

Clinical data
ATCvet code	Template:Infobox drug/formatATCvet Template:Infobox drug/formatATCvet
Legal status
Legal status	US: Rx-only, Unscheduled
Pharmacokinetic data
Bioavailability	87%
Protein binding	<5%
Elimination half-life	2½ hours
Excretion	Renal, unchanged
Identifiers
IUPAC name 1-[[(6R,7R)-7-[[(2Z)-(2-Amino-4-thiazolyl)-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0-oct-2-en-3-yl]methyl]-5,6,7,8-tetrahydroquinolinium inner salt
CAS Number	84957-30-2 Y
ChemSpider	16736863 Y
UNII	Z74S078CWP
KEGG	D07652 Y
ChEMBL	ChEMBL2103931
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C23H24N6O5S2
Molar mass	528.60 g/mol
3D model (JSmol)	Interactive image
SMILES O=C4[C@@H](NC(=O)C(=N\OC)/c1csc(N)n1)[C@H]5SC\C(C[n+]3cccc2CCCCc23)=C(/N45)C([O-])=O
InChI InChI=1S/C23H24N6O5S2/c1-34-27-16(14-11-36-23(24)25-14)19(30)26-17-20(31)29-18(22(32)33)13(10-35-21(17)29)9-28-8-4-6-12-5-2-3-7-15(12)28/h4,6,8,11,17,21H,2-3,5,7,9-10H2,1H3,(H3-,24,25,26,30,32,33)/b27-16-/t17-,21-/m1/s1 Y Key:YWKJNRNSJKEFMK-PQFQYKRASA-N Y
(verify)

WikiDoc Resources for Cefquinome
Articles
Most recent articles on Cefquinome Most cited articles on Cefquinome Review articles on Cefquinome Articles on Cefquinome in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cefquinome Images of Cefquinome Photos of Cefquinome Podcasts & MP3s on Cefquinome Videos on Cefquinome
Evidence Based Medicine
Cochrane Collaboration on Cefquinome Bandolier on Cefquinome TRIP on Cefquinome
Clinical Trials
Ongoing Trials on Cefquinome at Clinical Trials.gov Trial results on Cefquinome Clinical Trials on Cefquinome at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cefquinome NICE Guidance on Cefquinome NHS PRODIGY Guidance FDA on Cefquinome CDC on Cefquinome
Books
Books on Cefquinome
News
Cefquinome in the news Be alerted to news on Cefquinome News trends on Cefquinome
Commentary
Blogs on Cefquinome
Definitions
Definitions of Cefquinome
Patient Resources / Community
Patient resources on Cefquinome Discussion groups on Cefquinome Patient Handouts on Cefquinome Directions to Hospitals Treating Cefquinome Risk calculators and risk factors for Cefquinome
Healthcare Provider Resources
Symptoms of Cefquinome Causes & Risk Factors for Cefquinome Diagnostic studies for Cefquinome Treatment of Cefquinome
Continuing Medical Education (CME)
CME Programs on Cefquinome
International
Cefquinome en Espanol Cefquinome en Francais
Business
Cefquinome in the Marketplace Patents on Cefquinome
Experimental / Informatics
List of terms related to Cefquinome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cefquinome is a fourth-generation cephalosporin with pharmacological and antibacterial properties valuable in the treatment of coliform mastitis and other infections. It is only used in veterinary applications.

Properties

Cefquinome is resistant to beta-lactamase. Chemically, its zwitterionic structure can facilitate rapid penetration across biological membranes, including porins of bacterial cell walls. Plus, it has a higher affinity to target penicillin-binding proteins. The reactive site is a beta-lactam nucleus, while the main peripheral functional groups are a quaternary quinolinium, an aminothiazolyl moiety and an unusual O-alkylated oxime.

Cefquinome acts by inhibition of the cell wall synthesis, but it has a relatively short half-life of about 2.5 hours. It is less than 5% protein bound and is excreted unchanged in the urine.

Studies

Many studies have been conducted, mostly for animal use. One such study was conducted by the Pharma Research in Germany.

Test groups

Groups of albino mice, weighing 191 g, were dosed with 10 and 40 mg of cefquinome per kg. Blood samples were obtained from a cut at the tip of the tail and kept at 4°C. Urine was collected in metabolism cages.

Three male beagle dogs, weighing about 22 kg each, were dosed with 5, 10, and 20 mg/kg at the cephalic vein. Blood samples were drawn from the same vein in the opposite leg. Meanwhile, urine was collected by catheterization.

Pigs, five or six male and female in each group weighing about 18 kg each, were injected with 10 mg of cefquinome at the venajuglaris in the base of the left ear. Blood samples were withdrawn from the contralateral jugular vein.

Male and female calves weighing between 110 and 140 kg were dosed with 10 mg of cefquinome per kg through the vera jucular.

Standard solutions were prepared from pooled murine blood and urine taken from untreated dogs, pigs, and calves.

Calculations

Cefquinome concentrations were calculated by regression analysis, using the standard curves in which logarithms of the concentration were proportional to the areas of the inhibition zones. Curve fitting was carried out by nonlinear regression with the computer program PHAKOK. Pharmokinetic analysis of the concentration-time data after administration indicated that the best curve fits were usually achieved by using an open two-compartment model.

Conclusion

Data indicate that cefquinome has high antibacterial activity in vitro against nearly all strains tested. In general, cefquinome is within the same range as cefpirome and cefotaxime. Against Gram-negative species, cefquinome has very limited in vitro activity. The in vitro activity of cefquinome does not depend on the composition or pH of the test medium. The broad antibacterial spectrum and the high in vitro activity are reflected by high in vivo efficacy in experimental infections. In mouse models of septicemia, cefquinome possessed high therapetic efficacy. All infections were cured.

Treatment

In cattle, the injection should help against respiratory disease caused by Mannheimia haemolytica and Pasteurella multocida. It also helps with acute E. coli mastitis, dermatitis, infectious ulbar necrosis, and interdigital necrobacillosis. In calves, it is effective against E. coli septicaemia.

For pigs, it is used to treat bacterial infections of the lungs and respiratory tract caused by P. multocida, Haemophilus parasuis, Actinobacillus pleuropneumoniae, and Streptococcus suis. Mastitis-metritis-agalactia syndrome involved with E. coli, Staphylococcus, Streptococcus, and other cefquinome-sensitive organisms are also treated. In piglets, the mortality rate in cases of meningitis caused by Streptococcus sues is reduced. It is used in the treatment of mild or moderate lesions caused by Staphylococcus hyicus and arthritis caused by Streptococcus spp. and E. coli.

Caution/warnings

These are some factors to be aware of before treating:

• This product should not be used in animals known to be hypersensitive to β-lactam antibiotics.
• It should not be administered to animals with a body weight less than 1.25 kg.
• Use of the product may result in localised tissue reaction. Tissue lesions are repaired by 15 days after the last administration of the product.
• Hypersensitivity reactions to cephalosporins occur rarely.
• The product does not contain an antimicrobial preservative.
• To prevent the claimed infections in piglets, attention should be paid to hygiene and ventilation, and overcrowding should be avoided. When the first piglets are affected, careful examination of all animals in the same pen is recommended to enable an early treatment of any other infected piglets.

Clinical usage

Human use

Cefquinome is not approved for human use.

Veterinary medicine

Conditions of use are limited to therapeutic, parenteral, and individual animal use. Individual parenteral therapy of bovine respiratory disease data on cefquinome-related residues demonstrate only very small amounts are present in the intestinal tract of treated cattle with gastrointestinal activation. However, treatment should be short, meaning a single injection daily for about a week. Treatment should only be given by prescription. Cefquinome should not be used in feed or water.

Since 1994, in Europe, it was allowed to treat cattle by prescription only. In 1999, swine were included. By 2005, horses were allowed as well. In the United States, approval is pending for treatment of bovine respiratory disease. Even so, this is only available by prescription.

Cefquinome is also used for other illnesses, such as “shipping fever”, a pneumonia-like illness commonly found in cattle.

Concerns

Resistance and food-borne transmission

Of concern, the use of the drug in animals may lead to increases in antibiotic resistance. Humans can be exposed to bacteria through food-borne transmission, raising chances of becoming exposed to resistant bacterial species, such as Salmonella or E. coli. The potential for the development of antibiotic resistance increases as usage increases, by selecting bacteria which have acquired beta-lactamases.

Salmonella

The use may cause resistance in Salmonella present in the intestinal tract of the target animal. Resistant Salmonella may also contaminate the carcass at slaughter and transfer to humans when used as food. When humans are infected and treated with a fourth-generation cephalosporin, effectiveness may be compromised.

Although fourth-generation cephalosporin resistance is very rare, they are active against bacteria carrying the AmpC-type β-lactamase resistance mechanism. Since the late 1990s, the US and EU have surveyed and gathered data for fourth-generation cephalosporins for both human and veterinary use. Data indicate no changes occur in resistance patterns of relevant food-borne pathogens.

FDA guidelines

• Administered products will be used in individual animals for short duration and by prescription only.
• The extent of use is ranked low.
• Avoid human drug resistance to fourth-generation cephalosporins by authorizing extra-label prohibition.

See also

• Campylobacter
• Cefepime
• Cephalosporin
• Enterococcus
• Zwitterion